JFL Life Sciences Ltd
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.07JFL Life Sciences operates within the Healthcare Services industry, specifically hospitals and diagnostics. The company demonstrates notable strengths in solvency, growth, and coverage ratios. However, it shows weaknesses in liquidity, efficiency, financial metrics, and profitability. While the company exhibits strong growth and can comfortably cover its interest expenses, it struggles with generating profits and managing its short-term obligations. The absence of revenue growth and low financial ratios are areas that need attention. Overall, JFL Life Sciences needs to address its operational inefficiencies and enhance its profitability to ensure long-term sustainability. The company's strong growth and solvency provide a foundation for future improvement, but immediate action is required to tackle its current weaknesses.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio8.00
- Financial Ratio4.00
- Profitability Ratio6.20
- Efficiency Ratio4.67
- Coverage Ratio9.20
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursBearish
- 4 HoursBearish
- 1 DayBearish
- 1 WeekNeutral
- 1 MonthBearish
Health Score : 6.07JFL Life Sciences operates within the Healthcare Services industry, specifically hospitals and diagnostics. The company demonstrates notable strengths in solvency, growth, and coverage ratios. However, it shows weaknesses in liquidity, efficiency, financial metrics, and profitability. While the company exhibits strong growth and can comfortably cover its interest expenses, it struggles with generating profits and managing its short-term obligations. The absence of revenue growth and low financial ratios are areas that need attention. Overall, JFL Life Sciences needs to address its operational inefficiencies and enhance its profitability to ensure long-term sustainability. The company's strong growth and solvency provide a foundation for future improvement, but immediate action is required to tackle its current weaknesses.
Overall Valuation Score
P/E RATIO (TTM)
4.72
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
9.43
P/B RATIO
1.32
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
0.48
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
5.78
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹9.15 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Growth Score : 8.00JFL Life Sciences demonstrates strong growth in several key areas, notably in operating profit, EPS, assets, and net income. These positive trends suggest a company that is expanding effectively. However, the absence of revenue growth is a concern. Addressing the lack of revenue growth while maintaining progress in other areas could lead to even stronger overall performance.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 3.03 | 26.47 | 9.3 | 74.47 | 59.76 |
| Operating Profit Growth Rate | 150 | -20 | 25 | 60 | 50 |
| Earnings Per Share (EPS) Growth | -60.67 | -27.12 | 16.28 | 26 | 53.97 |
| Asset Growth Rate | 65.52 | 2.08 | 16.33 | 26.32 | 47.22 |
| Net Income Growth Rate | 200 | 0 | 0 | 33.33 | 50 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial Score : 4.00The financial ratios for JFL Life Sciences present a mixed picture. While capital expenditures are well-managed, the other ratios suggest that the company faces challenges in key financial metrics. The company needs to improve its earnings per share and book value per share to enhance overall financial performance.
Adjusted Earnings Per Share (Adjusted EPS)Poor
Cash Earnings Per Share (Cash EPS)WeakBook Value Per SharePoorDividend Per Share (DPS)PoorCapital Expenditures (CapEx)Excellent| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 3.75 | 2.73 | 2.73 | 1.21 | 1.82 |
| Cash Earnings Per Share (Cash EPS) | 3.75 | 2.73 | 2.73 | 1.52 | 2.12 |
| Book Value Per Share | 13.75 | 29.09 | 32.73 | 11.82 | 13.94 |
| Dividend Per Share (DPS) | 0 | 0 | 0.04 | 0 | 0 |
| Capital Expenditures (CapEx) | 1.7 | 0.2 | 6.1 | 0.4 | 3.4 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability Score : 6.20The profitability ratios for JFL Life Sciences show mixed results. Strong returns on capital employed and equity are offset by low margins. The company demonstrates a capability to generate returns on its investments, but its inability to translate this into higher profit margins is a concern. Focus on improving profit margins could significantly enhance overall profitability.
Gross Profit MarginPoorReturn on Capital Employed (ROCE)ExcellentReturn on Equity (ROE)ExcellentReturn on Assets (ROA)GoodOperating MarginPoorNet MarginPoor| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 14.71 | 9.3 | 10.64 | 8.54 | 8.4 |
| Return on Capital Employed (ROCE) | 23 | 15 | 12 | 16 | 18 |
| Return on Equity (ROE) | 27.27 | 9.38 | 8.33 | 10.26 | 13.04 |
| Return on Assets (ROA) | 10.42 | 8.16 | 8.77 | 11.11 | 11.32 |
| Operating Margin | 14.71 | 9.3 | 10.64 | 9.76 | 9.16 |
| Net Margin | 8.82 | 6.98 | 6.38 | 4.88 | 4.58 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency Score : 4.67The efficiency ratios for JFL Life Sciences present a mixed picture. While Days Sales in Inventory and Receivable Days are well-managed, the other ratios suggest potential inefficiencies in asset utilization. Improving these ratios could enhance overall operational performance. The company needs to focus on improving its asset turnover to enhance overall efficiency.
Fixed Asset Turnover RatioPoorInventory Turnover RatioPoorReceivables Turnover RatioPoorDays Sales in Inventory RatioExcellentReceivable DaysExcellentCapital Turnover RatioPoor| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 4.86 | 6.14 | 3.92 | 6.83 | 8.73 |
| Inventory Turnover Ratio | 2.67 | 2.79 | 2.9 | 3.85 | 4.17 |
| Receivables Turnover Ratio | 2.12 | 2.05 | 1.96 | 2.69 | 2.98 |
| Days Sales in Inventory Ratio | 136.7 | 130.82 | 125.86 | 94.81 | 87.53 |
| Receivable Days | 172.17 | 178.05 | 186.22 | 135.69 | 122.48 |
| Capital Turnover Ratio | 1.75 | 1.29 | 1.29 | 2.08 | 2.48 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage Score : 9.20The coverage ratios for JFL Life Sciences are strong, particularly the interest coverage ratio. This suggests that the company can comfortably meet its interest obligations. The company's ability to cover its obligations makes it a more stable and secure investment.
Interest Coverage RatioExcellentEquity Dividend Coverage RatioGood| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 3 | 5 | 5 | 7 | 5.5 |
| Equity Dividend Coverage Ratio | 12.5 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Solvency Score : 10.00JFL Life Sciences exhibits a very strong solvency position. This indicates a solid financial structure with a high degree of financial stability. The company's reliance on equity over debt can ensure long-term sustainability and reduces the risk of financial distress. This can provide a stable base for future growth and investment. The company is in a financially secure position.
Debt RatioExcellentDebt to Equity RatioExcellentEquity RatioExcellentDebt To Asset RatioExcellent| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.43 | 0.04 | 0.01 | 0.01 | 0.13 |
| Debt to Equity Ratio | 0.75 | 0.04 | 0.01 | 0.01 | 0.15 |
| Equity Ratio | 0.57 | 0.96 | 0.99 | 0.99 | 0.87 |
| Debt To Asset Ratio | 0.18 | 0.03 | 0.01 | 0.01 | 0.06 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Liquidity Score : 2.00The company's liquidity position appears very weak. This suggests that JFL Life Sciences may struggle to meet its short-term obligations. On a positive note, addressing these liquidity issues can significantly improve the company's financial stability. However, the company needs to improve its management of current assets and liabilities.
Current RatioPoorQuick RatioPoorCash RatioPoorOperating Cash Flow RatioPoor| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.44 | 2.66 | 2.17 | 1.86 | 1.71 |
| Quick Ratio | 0.91 | 1.84 | 1.38 | 1.15 | 1.06 |
| Cash Ratio | 0 | 0 | 0 | 0 | 0.02 |
| Operating Cash Flow Ratio | 0.07 | -0.57 | 0.39 | -0.12 | -0.07 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medicamen Organics Ltd | 6.30 | -6.94 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | Mono Pharmacare Ltd | 6.16 | 6.26 | Neutral | 8.00 | 1.75 | 3.00 |
| 3 | JFL Life Sciences Ltd | 6.07 | 9.43 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | Walpar Nutritions Ltd | 5.29 | 9.26 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | Mangalam Drugs and Organics Ltd | 4.50 | -1.07 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 7 | Sunrest Lifescience Ltd | 4.17 | 7.06 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
Balanced ManagementThe management of JFL Life Sciences shows a mixed performance. While the company has strong sales growth and improving operating profit margins, there are concerns about profit growth and working capital cycles. The stable promoter holding provides alignment.Overall, the management's effectiveness is mixed, requiring attention to profitability and efficiency.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth | 76% (TTM) | Strong sales growth. |
| Operating Profit Margin | 10.00% (Mar 2025) | Improving operational efficiency. | |
| Promoter Holding | 67.47% | High promoter holding. | |
| CONS | Profit Growth | 26% (TTM) | Inconsistent profit growth. |
| Working Capital Cycle | 185.75 Days (Mar 2025) | Stretched working capital cycle. |
Financial Performance & GrowthAverageCapital Efficiency & ReturnsAverageFinancial Health & PrudenceAverageShareholding & Ownership StructureGoodFinancial Performance & Growth
JFL Life Sciences shows strong revenue expansion but has inconsistent profit growth. Compounded Sales Growth is robust, with TTM at 76%. However, Compounded Profit Growth is 26% TTM. Quarterly results show a drop in YOY Sales Growth to -45.94% in Mar 2025. While the Operating Profit Margin (OPM) has improved to 11.76% in Mar 2025, inconsistencies in sales and profit growth need monitoring.
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Sales (Cr) | 31.78 | 30.17 | 32.77 | 33.59 | 42.83 | 46.55 | 82.04 |
| OPM (%) | 4.19% | 6.17% | 6.59% | 15.96% | 9.15% | 9.77% | 10.00% |
Capital Efficiency & Returns
ROCE and ROE reflect moderate returns, with ROCE at 15.81% and ROE at 11% (Last Year). The Cash Conversion Cycle is extended. ROCE % Mar 2020, Mar 2021, Mar 2022, Mar 2023, Mar 2024 and Mar 2025 are 11.74%, 10.26%, 23.13%, 15.41%, 11.47% and 15.81% respectively. The Cash Conversion Cycle has been fluctuating, with a value of 185.75 days in Mar 2025.
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash Conversion Cycle (Days) | 114.58 | 83.20 | 146.31 | 208.36 | 246.06 | 253.76 | 185.75 |
Financial Health & Prudence
Debt levels are moderate, with borrowings at 10.59 Cr in Mar 2025. Interest coverage seems adequate. The company has a dividend payout of 0.54%. Borrowings have fluctuated over the years.
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Borrowings (Cr) | 8.41 | 9.33 | 16.82 | 15.85 | 7.18 | 5.69 | 10.59 |
Shareholding & Ownership Structure
Promoter holding is stable at 67.47% from Sep 2022 to Mar 2025. The number of shareholders has remained relatively stable, with 997 shareholders in Mar 2025.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Promoter Holding (%) | 67.47% | 67.47% | 67.47% |
Balanced RiskJFL Life Sciences faces moderate risks. The extended cash conversion cycle and fluctuating sales growth indicate operational and market vulnerabilities. While promoter holding is stable and debt levels are manageable, the inconsistent profit growth and high debtor days suggest underlying financial and efficiency challenges.
Segment performance volatilityAverageSegment performance volatility
The quarterly sales growth shows volatility, with a drop in Mar 2025 (-45.94%). This indicates potential market or operational instability.
| Quarter | Mar 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|
| YOY Sales Growth (%) | N/A | N/A | -45.94% |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 109.34Bearish
- SMA 209.54Bearish
- SMA 509.77Bearish
- EMA 109.31Bearish
- EMA 209.46Bearish
- EMA 509.57Bearish
- DEMA 109.13Bullish
- DEMA 209.26Bearish
- DEMA 509.59Bearish
- TEMA 109.08Bullish
- TEMA 209.11Bullish
- TEMA 509.46Bearish
- MACD-0.17Bearish
- ADX25.14Strong Trend
- IndicatorValueSignal
- RSI37.44Neutral
- CCI-115.89Oversold
- ROC 9-3.68Bearish
- ROC 14-7.58Bearish
- ROC 25-4.19Bearish
- Stoch K2.08Oversold
- Stoch D0.69Oversold
- IndicatorValueSignal
- BB Upper10.14Neutral
- BB Middle9.54Neutral
- BB Lower8.95Neutral
- ATR0.11Low Volatility
- IndicatorValueSignal
- MFI34.02Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 109.38Bearish
- SMA 209.60Bearish
- SMA 509.49Bearish
- EMA 109.37Bearish
- EMA 209.51Bearish
- EMA 509.52Bearish
- DEMA 109.17Bearish
- DEMA 209.37Bearish
- DEMA 509.60Bearish
- TEMA 109.10Bullish
- TEMA 209.19Bearish
- TEMA 509.59Bearish
- MACD-0.12Bearish
- ADX24.83Weak Trend
- IndicatorValueSignal
- RSI40.25Neutral
- CCI-127.83Oversold
- ROC 9-3.68Bearish
- ROC 14-7.58Bearish
- ROC 25-7.58Bearish
- Stoch K2.08Oversold
- Stoch D9.79Oversold
- IndicatorValueSignal
- BB Upper10.19Neutral
- BB Middle9.60Neutral
- BB Lower9.00Neutral
- ATR0.15Low Volatility
- IndicatorValueSignal
- MFI34.02Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 109.52Bearish
- SMA 209.65Bearish
- SMA 509.39Bearish
- EMA 109.43Bearish
- EMA 209.49Bearish
- EMA 509.44Bearish
- DEMA 109.26Bearish
- DEMA 209.49Bearish
- DEMA 50N/AN/A
- TEMA 109.11Bullish
- TEMA 209.39Bearish
- TEMA 50N/AN/A
- MACD-0.03Bearish
- ADX21.10Weak Trend
- IndicatorValueSignal
- RSI43.70Neutral
- CCI-114.99Oversold
- ROC 9-8.50Bearish
- ROC 14-7.58Bearish
- ROC 25-1.08Bearish
- Stoch K1.28Oversold
- Stoch D0.43Oversold
- IndicatorValueSignal
- BB Upper10.41Neutral
- BB Middle9.65Neutral
- BB Lower8.89Neutral
- ATR0.24Low Volatility
- IndicatorValueSignal
- MFI45.76Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 109.69Bearish
- SMA 209.43Bearish
- SMA 509.41Bearish
- SMA 10010.20Bearish
- SMA 20011.71Bearish
- EMA 109.46Bearish
- EMA 209.46Bearish
- EMA 509.62Bearish
- EMA 10010.29Bearish
- EMA 20011.86Bearish
- DEMA 109.42Bearish
- DEMA 209.48Bearish
- DEMA 509.13Bullish
- DEMA 1008.70Bullish
- DEMA 2009.19Bearish
- TEMA 109.30Bearish
- TEMA 209.54Bearish
- TEMA 509.40Bearish
- TEMA 1008.97Bullish
- TEMA 2007.88Bullish
- MACD0.01Bearish
- ADX18.83Weak Trend
- IndicatorValueSignal
- RSI45.54Neutral
- CCI-66.67Neutral
- ROC 14-1.08Bearish
- ROC 25-2.14Bearish
- Stoch K34.31Neutral
- Stoch D42.48Neutral
- IndicatorValueSignal
- BB Upper10.21Neutral
- BB Middle9.43Neutral
- BB Lower8.64Neutral
- ATR0.37Low Volatility
- IndicatorValueSignal
- MFI53.09Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 209.75Bearish
- SMA 5011.51Bearish
- EMA 209.90Bearish
- EMA 5011.77Bearish
- DEMA 208.88Bullish
- DEMA 508.99Bullish
- TEMA 209.22Bullish
- TEMA 507.84Bullish
- MACD-0.71Bullish
- ADX14.44Weak Trend
- IndicatorValueSignal
- RSI42.65Neutral
- CCI-81.54Neutral
- ROC 14-12.01Bearish
- ROC 25-25.82Bearish
- Stoch K35.62Neutral
- Stoch D30.08Neutral
- IndicatorValueSignal
- BB Upper11.17Neutral
- BB Middle9.75Neutral
- BB Lower8.33Neutral
- ATR0.84Low Volatility
- IndicatorValueSignal
- MFI26.08Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 69.97Bearish
- SMA 1211.64Bearish
- SMA 2416.17Bearish
- EMA 610.05Bearish
- EMA 1211.79Bearish
- EMA 2413.55Bearish
- DEMA 68.57Bullish
- DEMA 129.04Bearish
- DEMA 24N/AN/A
- TEMA 68.76Bullish
- TEMA 127.84Bullish
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX18.49Weak Trend
- IndicatorValueSignal
- RSI45.95Neutral
- CCIN/AN/A
- ROC 25-35.34Bearish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper28.43Neutral
- BB Middle15.77Neutral
- BB Lower3.12Neutral
- ATR3.31Low Volatility
- IndicatorValueSignal
- MFI30.47Neutral